We Claim:

1. A method for treating allergic rhinitis in mammals which comprises administering a pharmaceutically effective amount of a composition comprising an anti-allergy agent selected from the group consisting of emedastine and olopatadine and a steroid selected from the group consisting of fluticasone, mometasone, budesonide and beclomethasone.

2. The method of Claim 1 wherein the amount of anti-allergy agent in the composition is 0.01 – 0.8 % (w/v) and the amount of steroid in the composition is 0.01 to 1.0 % (w/v).

3. The method of Claim 1 wherein the anti-allergy agent is olopatadine.

4. The method of Claim 3 wherein the steroid is fluticasone.

5. The method of Claim 1 wherein the steroid has an average particle size of 2.5 – 5 μm.

6. The method of Claim 1 wherein the steroid has an average particle size of less than 0.8 μm.

7. The method of Claim 6 wherein the steroid has an average particle size of 0.5 μm or less.

8. The method of Claim 1 wherein the composition is an aqueous composition packaged as a nasal spray.

9. The method of Claim 1 wherein the composition has a pH of 3.5 – 8.0 and a viscosity of 1 – 50 cps.

10. A method for treating allergic rhinitis in mammals which comprises administering a pharmaceutically effective amount of a composition comprising 0.1 – 0.8 % (w/v) of olopatadine and 0.02 – 0.5 % (w/v) of a steroid selected from the group consisting of fluticasone, mometasone, budesonide and beclomethasone, wherein the composition has a pH of 3.5 – 8.0 and a viscosity of 1 – 50 cps., and the composition is an aqueous composition packaged as a nasal spray.